These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37610133)

  • 21. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
    Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
    Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pathogenesis of, and pharmacological treatment for, Canavan disease.
    Wei H; Moffett JR; Amanat M; Fatemi A; Tsukamoto T; Namboodiri AM; Slusher BS
    Drug Discov Today; 2022 Sep; 27(9):2467-2483. PubMed ID: 35636725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Canavan disease: clinical features and recent advances in research.
    Hoshino H; Kubota M
    Pediatr Int; 2014 Aug; 56(4):477-83. PubMed ID: 24977939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Throughput Screening Cascade To Identify Human Aspartate
    Nešuta O; Thomas AG; Alt J; Hin N; Neužilová A; Long S; Tsukamoto T; Rojas C; Wei H; Slusher BS
    ACS Chem Neurosci; 2021 Sep; 12(18):3445-3455. PubMed ID: 34477360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Canavan disease and the role of N-acetylaspartate in myelin synthesis.
    Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN
    Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
    Eke GH; Iscan A; Cece H; Calik M
    Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions.
    Baslow MH; Guilfoyle DN
    Biochimie; 2013 Apr; 95(4):946-56. PubMed ID: 23151389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Redirecting
    Gessler DJ; Li D; Xu H; Su Q; Sanmiguel J; Tuncer S; Moore C; King J; Matalon R; Gao G
    JCI Insight; 2017 Feb; 2(3):e90807. PubMed ID: 28194442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell-Based Therapy for Canavan Disease Using Human iPSC-Derived NPCs and OPCs.
    Feng L; Chao J; Tian E; Li L; Ye P; Zhang M; Chen X; Cui Q; Sun G; Zhou T; Felix G; Qin Y; Li W; Meza ED; Klein J; Ghoda L; Hu W; Luo Y; Dang W; Hsu D; Gold J; Goldman SA; Matalon R; Shi Y
    Adv Sci (Weinh); 2020 Dec; 7(23):2002155. PubMed ID: 33304759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of central auditory processing in a mouse model of Canavan disease.
    von Jonquieres G; Froud KE; Klugmann CB; Wong AC; Housley GD; Klugmann M
    PLoS One; 2014; 9(5):e97374. PubMed ID: 24826990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Canavan disease: studies on the knockout mouse.
    Matalon R; Michals-Matalon K; Surendran S; Tyring SK
    Adv Exp Med Biol; 2006; 576():77-93; discussion 361-3. PubMed ID: 16802706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel aspartoacylase (ASPA) gene mutation in Canavan disease.
    Durmaz AA; Akin H; Onay H; Vahabi A; Ozkinay F
    Fetal Pediatr Pathol; 2012 Aug; 31(4):236-9. PubMed ID: 22468686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myelin lesion in the aspartoacylase (Aspa) knockout rat, an animal model for Canavan disease.
    Takeda S; Hoshiai R; Tanaka M; Izawa T; Yamate J; Kuramoto T; Kuwamura M
    Exp Anim; 2024 Jul; 73(3):347-356. PubMed ID: 38538326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Canavan disease: a white matter disorder.
    Kumar S; Mattan NS; de Vellis J
    Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual-function AAV gene therapy reverses late-stage Canavan disease pathology in mice.
    Fröhlich D; Kalotay E; von Jonquieres G; Bongers A; Lee B; Suchowerska AK; Housley GD; Klugmann M
    Front Mol Neurosci; 2022; 15():1061257. PubMed ID: 36568275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up after gene therapy for canavan disease.
    Leone P; Shera D; McPhee SW; Francis JS; Kolodny EH; Bilaniuk LT; Wang DJ; Assadi M; Goldfarb O; Goldman HW; Freese A; Young D; During MJ; Samulski RJ; Janson CG
    Sci Transl Med; 2012 Dec; 4(165):165ra163. PubMed ID: 23253610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
    Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
    J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atypical MRI findings in Canavan disease: a patient with a mild course.
    Yalcinkaya C; Benbir G; Salomons GS; Karaarslan E; Rolland MO; Jakobs C; van der Knaap MS
    Neuropediatrics; 2005 Oct; 36(5):336-9. PubMed ID: 16217711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel mutation in an Egyptian patient with infantile Canavan disease.
    Zaki OK; El Abd HS; Mohamed SA; Zayed H
    Metab Brain Dis; 2016 Jun; 31(3):573-7. PubMed ID: 26613958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renewal of oligodendrocyte lineage reverses dysmyelination and CNS neurodegeneration through corrected N-acetylaspartate metabolism.
    Lotun A; Li D; Xu H; Su Q; Tuncer S; Sanmiguel J; Mooney M; Baer CE; Ulbrich R; Eyles SJ; Strittmatter L; Hayward LJ; Gessler DJ; Gao G
    Prog Neurobiol; 2023 Jul; 226():102460. PubMed ID: 37149081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.